<DOC>
	<DOCNO>NCT02917746</DOCNO>
	<brief_summary>This multi-center , open-label , non-randomized control intervention study aim investigate treatment efficacy , side-effects quality life associate imiquimod treatment high-grade CIN lesion , alternative surgical treatment Large Loop Excision Transformation Zone ( LLETZ ) . Non-surgical treatment may prevent side-effects associated surgical treatment , premature birth subsequent pregnancy . The study hypothesis approximately 75 % patient high-grade CIN adequately treat imiquimod . 120 woman histological diagnosis CIN2 CIN3 include allocate one two treatment arm accord preference : 1 . Imiquimod treatment arm ( 60 patient ) . Patients group treat vaginal imiquimod 5 % cream 16 week . 2 . Standard treatment arm ( 60 patient ) . Patients group undergo LLETZ treatment .</brief_summary>
	<brief_title>Imiquimod Treatment High-grade CIN</brief_title>
	<detailed_description>Cervical Intraepithelial Neoplasia ( CIN ) premalignant condition cervical cancer . The standard treatment histologically confirm CIN2-3 surgical excision large loop excision transformation zone ( LLETZ ) . This procedure potential complication , hemorrhage , infection preterm birth subsequent pregnancy . For reason , non-invasive therapy need . Imiquimod cream study non-invasive treatment alternative high-grade CIN , evidence treatment efficacy limit evidence disease recurrence quality life treatment lack . One RCT perform show treatment high-grade CIN vaginal imiquimod cream lead disease regression 73 % . Side-effects generally mild , common . A recent survey among gynecologist patient preference study indicate imiquimod treatment high-grade CIN mainly prefer select population woman future pregnancy wish . These woman accept low treatment efficacy high rate side-effects imiquimod treatment order prevent future preterm birth cause LLETZ treatment . Ideally , woman high probability successful treatment would select . The objective study investigate treatment efficacy , side-effects quality life associate imiquimod treatment high-grade CIN lesion select population patient prefer imiquimod treatment instead LLETZ . The study also aim identify predictive biomarkers clinical response imiquimod treatment , order select patient good treatment response expect . The study design multicenter , open-label , non-randomized control intervention study . 120 woman histological diagnosis CIN2 CIN3 include allocate one two treatment arm accord preference : 1 . Imiquimod treatment arm ( 60 patient ) . Patients group treat vaginal imiquimod 5 % cream 16 week . 2 . Standard treatment arm ( 60 patient ) . Patients group undergo LLETZ treatment . A control colposcopy perform 10 week imiquimod group . In case progressive disease , treatment end LLETZ perform treatment . For patient treatment continue , treatment efficacy evaluate 20 week , colposcopy diagnostic biopsy . Statistical analysis perform base intention-to-treat analysis . The primary study endpoint : - Treatment efficacy imiquimod LLETZ treatment , define regression CIN1 le 20 week imiquimod need additional therapy within 6 month LLETZ treatment . - Identification predictive biomarkers efficacy imiquimod treatment individual patient , base biomarkers reflect host , virus cellular factor . Secondary study endpoint : - Side effect imiquimod therapy LLETZ therapy . - Disease recurrence 6 , 12 24 month follow-up . - Quality life ( QoL ) , treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>de novo CIN2 CIN3 lesion , histologically confirm diagnostic biopsy age 18 year older previous histologically confirm highgrade CIN ( CIN 23 ) concomitant vulvar and/or vaginal intraepithelial neoplasia previous cervical malignancy current malignant disease immunodeficiency ( include HIV/AIDS immunodepressive medication ) pregnancy lactation legal incapability</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cervical intraepithelial neoplasia</keyword>
	<keyword>Imiquimod</keyword>
	<keyword>Treatment</keyword>
	<keyword>Predictive biomarkers</keyword>
</DOC>